Anti-CTLA4: Issues in Development and Regulatory Approval
November 2, 2008
Westin Gaslamp Quarter Hotel
San Diego, CA
Schedule at a Glance (subject to change)
| Sunday, November 2, 2008 |
| 10:30 am - 10:35 am |
Introduction
Ulrich Keilholz, MD - Charité CBF |
| 10:35 am - 10:45 am |
Review of Ipilmumab Development Program and Data
Jeffrey S. Weber, MD, PhD - H. Lee Moffitt Cancer Center and Research Institute
|
| 10:45 am - 10:55 am |
Review of Tremilmumab Development Program and Data
Antoni Ribas, MD - UCLA Medical Center |
| 10:55 am - 11:05 am |
Comparison of Development Plans of IL2 and CTLA4 Abs
Mario Sznol, MD - Yale University School of Medicine |
| 11:05 am - 11:15 am |
Evaluation of IL2/Anti-CTLA4 Type Activity Data
Steven Hirschfeld, MD, PhD - National Institute of Child Health and Human Development |
| 11:15 am - 11:20 am |
Introduction into the Panel and Audience Discussion
Michael B. Atkins, MD - Beth Israel Deaconess Medical Center
|
| 11:20 am - 11:59 am |
Panel Discussion / Audience Questions |
| 11:59 am - 12:00 pm |
Closing Remarks
Ulrich Keilholz, MD - Charité CBF
|
| 12:00 pm |
Adjourn |
